Cellectis SA (CLLS NASDAQ) stock market data APIs
$4.7322
0.1(2.1%)
as of November 20, 2025
Try our APIs with
free plan!
Cellectis SA Financial Data Overview
Price chart is built with
Anychart
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company was founded in 1999 and is headquartered in Paris, France.
Prev. Close
4.7322
Open
4.8362
High
4.9473
Low
4.5131
52 wk Range
1.1-5.4796
Market Cap
496 M
Shares Outstanding
72 325 K
Revenue
82 551 K
EPS
0.02
Beta
3.042
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cellectis SA data using free add-ons & libraries
Get Cellectis SA Fundamental Data
Cellectis SA Fundamental data includes:
- Net Revenue: 82 551 K
- EBITDA: -13 874 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-10
- EPS/Forecast: -0.248
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cellectis SA News
New
Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells
NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform...
Cellectis publie un article dans Nature Communications sur un procédé d’édition génomique non viral efficace pour l’insertion génique dans les cellules souches hématopoïétiques
NEW YORK, 19 nov. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génom...
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: * Applied Materials (AMAT [https://seekingalpha.com/symbol/AMAT]) * Virgin Galactic Holdings (SPCE [https://seekingalpha.com/symbol/SPC...
Cellectis Q3 2025 Earnings Preview
* Cellectis (CLLS [https://seekingalpha.com/symbol/CLLS]) is scheduled to announce Q3 earnings results on Thursday, November 13th, after market close. * The consensus EPS Estimate is -$0.11 [https...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
